These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1675865)

  • 1. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
    van Holten-Verzantvoort AT; Zwinderman AH; Aaronson NK; Hermans J; van Emmerik B; van Dam FS; van den Bos B; Bijvoet OL; Cleton FJ
    Eur J Cancer; 1991; 27(5):544-9. PubMed ID: 1675865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
    van Holten-Verzantvoort AT; Hermans J; Beex LV; Blijham G; Cleton FJ; van Eck-Smit BC; Sleeboom HP; Papapoulos SE
    Eur J Cancer; 1996 Mar; 32A(3):450-4. PubMed ID: 8814691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative pamidronate treatment in patients with bone metastases from breast cancer.
    van Holten-Verzantvoort AT; Kroon HM; Bijvoet OL; Cleton FJ; Beex LV; Blijham G; Hermans J; Neijt JP; Papapoulos SE; Sleeboom HP
    J Clin Oncol; 1993 Mar; 11(3):491-8. PubMed ID: 7680374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
    van Holten-Verzantvoort AT; Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
    van Holten-Verzantvoort AT; Bijvoet OL; Cleton FJ; Hermans J; Kroon HM; Harinck HI; Vermey P; Elte JW; Neijt JP; Beex LV
    Lancet; 1987 Oct; 2(8566):983-5. PubMed ID: 2889957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous pamidronate for metastatic bone pain.
    Purohit OP; Anthony C; Radstone CR; Owen J; Coleman RE
    Br J Cancer; 1994 Sep; 70(3):554-8. PubMed ID: 8080746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
    Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
    Hultborn R; Gundersen S; Rydén S; Holmberg E; Carstensen J; Wallgren UB; Kilany S
    Acta Oncol; 1996; 35 Suppl 5():73-4. PubMed ID: 9142971
    [No Abstract]   [Full Text] [Related]  

  • 14. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy.
    Cascinu S; Casadei V; Del Ferro E; Alessandroni P; Catalano G
    Support Care Cancer; 1996 Jan; 4(1):31-3. PubMed ID: 8771291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
    Hultborn R; Gundersen S; Ryden S; Holmberg E; Carstensen J; Wallgren UB; Killany S; Andreassen L; Carlsson G; Fahl N; Hatschek T; Sommer HH; Hessman Y; Hornmark-Stenstam B; Johnsborg S; Klepp R; Laino R; Niklasson LG; Rudenstam CM; Sundbeck A; Söderberg M; Tejler G
    Anticancer Res; 1999; 19(4C):3383-92. PubMed ID: 10629624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
    Thürlimann B; Morant R; Jungi WF; Radziwill A
    Support Care Cancer; 1994 Jan; 2(1):61-5. PubMed ID: 8156259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
    Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
    Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
    Kristensen B; Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Bjerregaard B; Cold S; Edlund P; Ewertz M; Kamby C; Lindman H; Nordenskjöld B; Bergh J
    Acta Oncol; 2008; 47(4):740-6. PubMed ID: 18465343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.